Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study

다국어 초록 (Multilingual Abstract)

OBJECTIVE: A numerical score, the peritoneal cancer index (PCI), was developed to reflect the extent of tumor growth in gastric and colorectal cancers and to tailor treatment. This study aimed to examine the value of the PCI score in advanced epithelial ovarian cancer (EOC) regarding completeness of surgical cytoreduction and survival.
METHODS: This was a prospective observational cohort study. Patients with primary serous EOC at International Federation of Gynecology and Obstetrics (FIGO) stages IIIB or higher were included. Patients with FIGO stage IVB as well as those assigned to receive neoadjuvant treatment were excluded from the study. The PCI was obtained and registered intraoperatively.
RESULTS: In the study period we recruited 96 patients with serous EOC stage IIIB-IVA. A PCI score cut-off value of 13 was calculated using a receiver operator characteristic (ROC) curve, above which worse survival is expected (area under the curve [AUC]=0.641; 95% confidence interval [CI]=0.517-0.765; sensitivity and specificity 80.6%, 45.0%, respectively; p=0.050). A multivariate analysis determined that suboptimal surgical cytoreduction was the only independent predictive factor for recurrence (odds ratio [OR]=7.548; 95% CI=1.473-38.675; p=0.015). A multivariate analysis determined that only suboptimal surgical cytoreduction (hazard ratio [HR]=2.33; 95% CI=0.616-8.795; p=0.005), but not PCI score >13 (HR=1.289; 95% CI=0.329-5.046; p=0.716), was an independent predictive factor for death.
CONCLUSION: We conclude from this study that the PCI score is a reliable tool helping to assess the extent of disease in advanced serous EOC patients and may help predicting complete surgical cytoreduction but cannot qualify as a predictor of survival.

참고문헌 (Reference)

1 Vidal F, "Which surgical attitude to choose in the context of non-resectability of ovarian carcinomatosis: beyond gross residual disease considerations" 23 : 434-442, 2016

2 Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group" 5 : 649-655, 1982

3 Hoskins WJ, "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma" 170 : 974-979, 1994

4 Harter P, "Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland regarding the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer" 76 : 147-149, 2016

5 Leitlinienprogramm Onkologie (DE), "S3-leitlinie diagnostik, therapie und nachsorge maligner ovarialtumoren" Zuckschwerdt 2013

6 du Bois A, "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)" 115 : 1234-1244, 2009

7 Los G, "Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin" 69 : 235-241, 1994

8 Khoury-Collado F, "Recent surgical management of ovarian cancer" 37 : 379-382, 2011

9 Lampe B, "Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma" 25 : 135-144, 2015

10 Cavaliere F, "Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O." 37 : 148-154, 2011

11 Gasimli K, "Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer" 22 : 2729-2737, 2015

12 Vergote I, "Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer" 47 : S88-S92, 2011

13 Kehoe S, "Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial" 386 : 249-257, 2015

14 Elias D, "Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study" 28 : 63-68, 2010

15 Sugarbaker PH, "Peritoneal carcinomatosis: principles of management" Kluwer Academic Publishers 1996

16 Bakrin N, "Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients" 39 : 1435-1443, 2013

17 Canbay E, "Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan" 21 : 1147-1152, 2014

18 Vergote I, "Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer" 363 : 943-953, 2010

19 Luyckx M, "Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study" 22 : 1337-1343, 2012

20 Kaatsch P, "Krebs in Deutschland 2009/2010" Robert Koch-Institut 2013

21 Trimbos JB, "Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial" 95 : 113-125, 2003

22 Hotouras A, "Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review" 26 : 661-670, 2016

23 Torre LA, "Global cancer statistics, 2012" 65 : 87-108, 2015

24 American Cancer Society, "Global cancer facts & figures 2007" American Cancer Society 2007

25 Goere D, "Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study" 22 : 2958-2964, 2015

26 Akaboshi M, "Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II)" 66 : 215-220, 1994

27 Pavlov MJ, "Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12-year single center experience" 35 : 1186-1191, 2009

28 Gonzalez Bayon L, "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?" 39 : 1109-1115, 2013

29 Deraco M, "Cytoreductive surgery & perioperative intraperitoneal chemotherapy for peritoneal surface malignancy: textbook and video atlas" Cine-Med 2012

30 Cascales-Campos P, "Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients" 179 : 88-93, 2014

31 da Silva RG, "Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer" 203 : 878-886, 2006

32 Chiva LM, "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" 136 : 130-135, 2015